Assignee
FULCRUM THERAPEUTICS INC
US·7 granted patents·11 pending applications·15 citations·filing 2018–2024
Top patents by PatentIndex Score
18 records- 0194US10973805B2Macrocyclic azolopyridine derivatives as EED and PRC2 modulatorsFULCRUM THERAPEUTICS INC·Filed 2020·Granted Apr 13, 2021·5 cites·20 claims
- 0291US11590111B2Macrocyclic azolopyridine derivatives as EED and PRC2 modulatorsFULCRUM THERAPEUTICS INC·Filed 2021·Granted Feb 28, 2023·2 cites·10 claims
- 0388US10342786B2P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHDFULCRUM THERAPEUTICS INC·Filed 2018·Granted Jul 9, 2019·4 cites·19 claims
- 0486US10537560B2P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHDFULCRUM THERAPEUTICS INC·Filed 2018·Granted Jan 21, 2020·4 cites·28 claims
- 0583US2025195480A1Macrocyclic azolopyridine derivatives as eed and prc2 modulatorsFULCRUM THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0681US12109198B2Macrocyclic azolopyridine derivatives as EED and PRC2 modulatorsFULCRUM THERAPEUTICS INC·Filed 2022·Granted Oct 8, 2024·0 cites·5 claims
- 0777US2023257743A1Use of p38 inhibitors to reduce expression of dux4FULCRUM THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 0875US2022282254A1P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshdFULCRUM THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 0972US2022133704A1P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshdFULCRUM THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1070US11479770B2Use of p38 inhibitors to reduce expression of DUX4FULCRUM THERAPEUTICS INC·Filed 2018·Granted Oct 25, 2022·0 cites·8 claims
- 1167US11291659B2P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHDFULCRUM THERAPEUTICS INC·Filed 2020·Granted Apr 5, 2022·0 cites·15 claims
- 1261US2025213543A1An embryonic ectoderm development inhibitor for the treatment of sickle cell diseaseFULCRUM THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1357US2024199645A1Polymorphic forms of (s)-12-fluoro-4-(1-methyl-1h-pyrazol-5-yl)-7a,8,13,14-tetrahydro-7h-[1,2,4]triazolo[4',3':1,6]pyrido[3,2-b]benzofuro[4,3-fg][1,4]oxazonineFULCRUM THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1451US2025223560A1Nox4 inhibitor compositions and methods for regeneration of dystrophic muscleFULCRUM THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1551US2024342148A1Methods of treating facioscapulohumeral muscular dystrophy with losmapimodFULCRUM THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1649US2024238296A1Methods of regulating bcl11a expression and treatment of bcl11a-mediated disordersFULCRUM THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1749US2022017908A1Compositions and methods for increasing fetal hemoglobin and treating sickle cell diseaseFULCRUM THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 1846US2024368185A1Macrocyclic azolopyridinesFULCRUM THERAPEUTICS INC·Filed 2022·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when FULCRUM THERAPEUTICS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →